JP2004536077A5 - - Google Patents

Info

Publication number

JP2004536077A5

JP2004536077A5 JP2003501483A JP2003501483A JP2004536077A5 JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5 JP 2003501483 A JP2003501483 A JP 2003501483A JP 2003501483 A JP2003501483 A JP 2003501483A JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5

Authority

JP

Japan

Prior art keywords

composition according

polypeptide

sequence

sequence seq

similarity

Prior art date

2002-05-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229920001184 polypeptide Polymers 0.000 claims description 5
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
• 206010022979 Iron excess Diseases 0.000 claims description 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
• 102000039446 nucleic acids Human genes 0.000 claims description 2
• 108020004707 nucleic acids Proteins 0.000 claims description 2
• 150000007523 nucleic acids Chemical class 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 claims 3
• XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 2
• 208000018565 Hemochromatosis Diseases 0.000 claims 2
• 235000001014 amino acid Nutrition 0.000 claims 2
• 150000001413 amino acids Chemical class 0.000 claims 2
• 230000005714 functional activity Effects 0.000 claims 2
• 102000018511 hepcidin Human genes 0.000 claims 2
• 229940066919 hepcidin Drugs 0.000 claims 2
• 108060003558 hepcidin Proteins 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• 208000031229 Cardiomyopathies Diseases 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000014018 liver neoplasm Diseases 0.000 claims 1
• 238000002105 Southern blotting Methods 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 101100338774 Mus musculus Hamp gene Proteins 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• NMROINAYXCACKF-WHFBIAKZSA-N Gly-Cys-Cys Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O NMROINAYXCACKF-WHFBIAKZSA-N 0.000 description 1
• ZPVJJPAIUZLSNE-DCAQKATOSA-N His-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O ZPVJJPAIUZLSNE-DCAQKATOSA-N 0.000 description 1
• WTOAPTKSZJJWKK-HTFCKZLJSA-N Ile-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N WTOAPTKSZJJWKK-HTFCKZLJSA-N 0.000 description 1
• RLZDUFRBMQNYIJ-YUMQZZPRSA-N Lys-Cys-Gly Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N RLZDUFRBMQNYIJ-YUMQZZPRSA-N 0.000 description 1
• TWTNGJMBFRTKEX-FXQIFTODSA-N Met-Cys-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O TWTNGJMBFRTKEX-FXQIFTODSA-N 0.000 description 1
• 101100338766 Mus musculus Hamp2 gene Proteins 0.000 description 1
• AEEQKUDWJGOFQI-SRVKXCTJSA-N Phe-Cys-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N AEEQKUDWJGOFQI-SRVKXCTJSA-N 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 125000003275 alpha amino acid group Chemical group 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003814 drug Substances 0.000 description 1